Evidence map›Paper›PMID 26048034›Full record

Trial reportOrphanet journal of rare diseases2015

Alpha-mannosidosis: correlation between phenotype, genotype and mutant MAN2B1 subcellular localisation.

Line Borgwardt, Hilde Monica Frostad Riise Stensland, Klaus Juul Olsen, Flemming Wibrand, Helle Bagterp Klenow, Michael Beck, Yasmina Amraoui, Laila Arash, Jens Fogh, Øivind Nilssen and 2 more

3 registry-linked trialsOpen access · goldAbstract readClinical Trial
In one paragraph

Trial report in Orphanet journal of rare diseases, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00498420 completednot on this map

A Multicenter, Multinational Study That Will Evaluate Clinical and Surrogate Parameters Known to be Affected in Alpha-Mannosidosis Patients

TypeobservationalSponsorZymenex A/SRan2007 to 2009Enrolled45ConditionsAlpha Mannosidosis
NCT01268358 phase1completednot on this map

A Single Center, Open-label, Dose Escalation Study of the Safety and Pharmacokinetics of rhLAMAN (Recombinant Human Alpha-mannosidase or Lamazym) for the Treatment of Patients With Alpha-mannosidosis.

TypeinterventionalSponsorZymenex A/SRan2010 to 2011Enrolled10ConditionsAlpha MannosidosisArmsLamazym
NCT01681953 phase3completednot on this map

A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel Group Trial, Investigating the Efficacy and Safety of Repeated Lamazym Treatment of Subjects With Alpha-Mannosidosis.

TypeinterventionalSponsorZymenex A/SRan2012 to 2014Enrolled25ConditionsAlpha-MannosidosisArmsLamazym, Placebo
3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 59 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Characterizing circulating biomarkers for childhood dementia disorders: A scoping review of clinical trials.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2025
    Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. A HomozygousGenes · 2023
    Article
  13. Article
  14. Article
  15. Relationship betweenJIMD reports · 2023
    Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 3 countries.

Line BorgwardtDepartment of Clinical Genetics, Centre for Inherited Metabolic Diseases, Copenhagen University Hospital Rigshospitalet, 9 Blegdamsvej, 2100, Copenhagen, Denmark. line.gutte.borgwardt@regionh.dk.
Hilde Monica Frostad Riise StenslandDepartment of Medical Genetics, Division of Child and Adolescent Health, University Hospital of North Norway, Tromsø, Norway. hilde.monica.stensland@unn.no.
Klaus Juul OlsenLarix, CRO, Ballerup, Denmark. kjo@larix.dk.
Flemming WibrandDepartment of Clinical Genetics, Centre for Inherited Metabolic Diseases, Copenhagen University Hospital Rigshospitalet, 9 Blegdamsvej, 2100, Copenhagen, Denmark. Flemming.Wibrand@regionh.dk.
Helle Bagterp KlenowDepartment of Medical Genetics, Division of Child and Adolescent Health, University Hospital of North Norway, Tromsø, Norway. helle.klenow@unn.no.
Michael BeckZentrum für Kinder - und Jugendmedizin, Villa Metabolica, Mainz, Germany. Dr.M.Beck@t-online.de.
Yasmina AmraouiZentrum für Kinder - und Jugendmedizin, Villa Metabolica, Mainz, Germany. Yasmin.Amraoui@unimedizin-mainz.de.
Laila ArashZentrum für Kinder - und Jugendmedizin, Villa Metabolica, Mainz, Germany. Laila.Arash-Kaps@unimedizin-mainz.de.
Jens FoghZymenex A/S (Chiesi Group), Hilleroed, Denmark. jf@zymenex.com.
Øivind NilssenDepartment of Medical Genetics, Division of Child and Adolescent Health, University Hospital of North Norway, Tromsø, Norway. oivind.nilssen@uit.no.
Christine I DaliDepartment of Clinical Genetics, Centre for Inherited Metabolic Diseases, Copenhagen University Hospital Rigshospitalet, 9 Blegdamsvej, 2100, Copenhagen, Denmark. christine.I.dali@regionh.dk.
Allan Meldgaard LundDepartment of Clinical Genetics, Centre for Inherited Metabolic Diseases, Copenhagen University Hospital Rigshospitalet, 9 Blegdamsvej, 2100, Copenhagen, Denmark. allan.meldgaard.lund@regionh.dk.
Copenhagen University Hospital · DKUniversity Hospital of North Norway · NOZentrum für Kinderheilkunde · DERigshospitalet · DKZymenex (Denmark) · DK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAlpha-mannosidosis is caused by mutations in MAN2B1, leading to loss of lysosomal alpha-mannosidase activity. Symptoms include intellectual disabilities, hearing impairment, motor function disturbances, facial coarsening and musculoskeletal abnormalities.

methodsTo study the genotype-phenotype relationship for alpha-mannosidosis 66 patients were included. Based on the predicted effect of the mutations and the subcellular localisation of mutant MAN2B1 in cultured cells, the patients were divided into three subgroups. Clinical and biochemical data were collected. Correlation analyses between each of the three subgroups of genotype/subcellular localisation and the clinical and biochemical data were done to investigate the potential relationship between genotype and phenotype in alpha-mannosidosis. Statistical analyses were performed using the SPSS software. Analyses of covariance were performed to describe the genotype-phenotype correlations. The phenotype parameters were modelled by the mutation group and age as a covariate. P values of <0.05 were considered as statistically significant.

resultsComplete MAN2B1 genotypes were established for all patients. We found significantly higher scores in the Leiter-R test, lower concentrations of CSF-oligosaccharides, higher point scores in the Bruininks-Oseretsky Test of Motor Proficiency subtests (BOT-2); Upper limb coordination and Balance, and a higher FVC% in patients in subgroup 3, harbouring at least one variant that allows localisation of the mutant MAN2B1 protein to the lysosomes compared to subgrou 2 and/or subgroup 1 with no lysosomal localization of the mutant MAN2B1 protein.

conclusionOur results indicate a correlation between the MAN2B1 genotypes and the cognitive function, upper limb coordination, balance, FVC% and the storage of oligosaccharides in CSF. This correlation depends on the subcellular localisation of the mutant MAN2B1 protein.

Indexed as

AdolescentAdultalpha-MannosidosisChildChild, PreschoolFemaleGenetic Association StudiesGenotypeHumansMaleMannosidasesOligosaccharidesPhenotypeYoung AdultMannosidasesOligosaccharides

Identifiers

PMID26048034
PMCPMC4465300
OpenAlexW1570427382

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.